Halozyme Therapeutics (HALO) Competitors $59.25 +0.84 (+1.44%) Closing price 04/24/2025 04:00 PM EasternExtended Trading$59.38 +0.13 (+0.23%) As of 07:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock HALO vs. BIIB, UTHR, BMRN, INCY, NBIX, EXEL, EXAS, RGEN, MDGL, and IONSShould you be buying Halozyme Therapeutics stock or one of its competitors? The main competitors of Halozyme Therapeutics include Biogen (BIIB), United Therapeutics (UTHR), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), Exact Sciences (EXAS), Repligen (RGEN), Madrigal Pharmaceuticals (MDGL), and Ionis Pharmaceuticals (IONS). These companies are all part of the "biotechnology" industry. Halozyme Therapeutics vs. Biogen United Therapeutics BioMarin Pharmaceutical Incyte Neurocrine Biosciences Exelixis Exact Sciences Repligen Madrigal Pharmaceuticals Ionis Pharmaceuticals Halozyme Therapeutics (NASDAQ:HALO) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, dividends, profitability, valuation, risk, media sentiment and analyst recommendations. Does the MarketBeat Community favor HALO or BIIB? Biogen received 1290 more outperform votes than Halozyme Therapeutics when rated by MarketBeat users. Likewise, 71.41% of users gave Biogen an outperform vote while only 69.47% of users gave Halozyme Therapeutics an outperform vote. CompanyUnderperformOutperformHalozyme TherapeuticsOutperform Votes52869.47% Underperform Votes23230.53% BiogenOutperform Votes181871.41% Underperform Votes72828.59% Do institutionals and insiders hold more shares of HALO or BIIB? 97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 2.9% of Halozyme Therapeutics shares are owned by insiders. Comparatively, 0.2% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media refer more to HALO or BIIB? In the previous week, Biogen had 7 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 30 mentions for Biogen and 23 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 0.92 beat Biogen's score of 0.91 indicating that Halozyme Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 13 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Biogen 16 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, HALO or BIIB? Biogen has higher revenue and earnings than Halozyme Therapeutics. Biogen is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHalozyme Therapeutics$1.02B7.21$281.59M$3.4317.27Biogen$9.68B1.81$1.63B$11.1910.68 Do analysts prefer HALO or BIIB? Halozyme Therapeutics currently has a consensus target price of $62.89, indicating a potential upside of 6.14%. Biogen has a consensus target price of $211.37, indicating a potential upside of 76.86%. Given Biogen's higher probable upside, analysts plainly believe Biogen is more favorable than Halozyme Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Halozyme Therapeutics 0 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.60Biogen 0 Sell rating(s) 18 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.42 Is HALO or BIIB more profitable? Halozyme Therapeutics has a net margin of 43.74% compared to Biogen's net margin of 16.87%. Halozyme Therapeutics' return on equity of 157.78% beat Biogen's return on equity.Company Net Margins Return on Equity Return on Assets Halozyme Therapeutics43.74% 157.78% 25.34% Biogen 16.87%14.98%8.76% Which has more volatility and risk, HALO or BIIB? Halozyme Therapeutics has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.06, indicating that its stock price is 94% less volatile than the S&P 500. SummaryHalozyme Therapeutics beats Biogen on 10 of the 18 factors compared between the two stocks. Get Halozyme Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HALO vs. The Competition Export to ExcelMetricHalozyme TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.32B$2.93B$5.41B$7.70BDividend YieldN/A1.91%5.44%4.33%P/E Ratio17.2730.4322.1818.31Price / Sales7.21478.52397.31107.04Price / Cash12.35168.6838.2034.62Price / Book20.083.786.834.25Net Income$281.59M-$72.06M$3.20B$247.51M7 Day Performance0.78%11.17%5.77%6.86%1 Month Performance-8.62%-4.87%-4.32%-2.95%1 Year Performance54.06%-18.74%17.88%5.17% Halozyme Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HALOHalozyme Therapeutics4.4083 of 5 stars$59.25+1.4%$62.89+6.1%+51.5%$7.32B$1.02B17.27390News CoverageBIIBBiogen4.767 of 5 stars$116.49-1.8%$213.15+83.0%-40.8%$17.05B$9.68B10.418,720Analyst ForecastNews CoverageUTHRUnited Therapeutics4.9313 of 5 stars$284.25-0.2%$395.67+39.2%+25.1%$12.77B$2.88B12.48980Upcoming EarningsInsider TradePositive NewsBMRNBioMarin Pharmaceutical4.8932 of 5 stars$58.65-0.9%$94.00+60.3%-31.2%$11.19B$2.85B26.663,080Upcoming EarningsINCYIncyte4.8462 of 5 stars$56.80-2.4%$74.69+31.5%+14.0%$10.99B$4.24B210.382,320Upcoming EarningsNBIXNeurocrine Biosciences4.8243 of 5 stars$100.68-0.7%$161.86+60.8%-23.9%$9.96B$2.36B30.601,200Upcoming EarningsAnalyst ForecastAnalyst RevisionEXELExelixis4.3066 of 5 stars$35.59-1.7%$37.59+5.6%+56.9%$9.96B$2.17B20.111,220Upcoming EarningsPositive NewsEXASExact Sciences4.2766 of 5 stars$43.10+3.7%$69.25+60.7%-27.9%$8.01B$2.76B-7.746,400Upcoming EarningsAnalyst RevisionNews CoveragePositive NewsRGENRepligen4.5559 of 5 stars$131.64+1.3%$176.82+34.3%-13.5%$7.39B$634.44M-258.122,020Upcoming EarningsNews CoverageMDGLMadrigal Pharmaceuticals4.4875 of 5 stars$295.02-2.2%$378.44+28.3%+56.3%$6.51B$180.13M-11.7690Analyst ForecastPositive NewsIONSIonis Pharmaceuticals3.9772 of 5 stars$28.51+0.4%$56.72+99.0%-30.3%$4.53B$705.14M-9.38800Upcoming Earnings Related Companies and Tools Related Companies BIIB Competitors UTHR Competitors BMRN Competitors INCY Competitors NBIX Competitors EXEL Competitors EXAS Competitors RGEN Competitors MDGL Competitors IONS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HALO) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Halozyme Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy HALO Stock Free HALO Stock Alerts